Taken together, these data confirm that the genomic amplification of BCR/ABL1 fusion that occurs in some CML patients during disease progression also involves amplification of 9q34 gene-rich sequences downstream of ABL1 breakpoint. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.